GRAND RAPIDS — A $40 million investment by a Japanese pharmaceutical company provides Tetra Discovery Partners Inc. a strategic partner and capital to test and commercialize a new drug compound that could treat Alzheimer’s disease and a form of autism.

Published in Health Care